Key takeaways
Eliquis (apixaban) and Xarelto (rivaroxaban) are both direct-acting oral anticoagulants (DOACs) used to prevent and treat blood clots. Both medications are effective in reducing the risk of stroke and treating conditions caused by blood clots, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Xarelto is also FDA approved for other heart-related conditions, such as coronary artery disease and, when combined with aspirin, peripheral artery disease. Eliquis is typically taken twice daily and might have a lower risk of bleeding compared to Xarelto, which is often taken once daily. Neither medication requires frequent blood tests or that you follow dietary restrictions like the traditional blood thinner warfarin (Jantoven) does. Eliquis may be preferable for patients with kidney problems. Common side effects for both medications include bleeding and bruising. Serious risks include life-threatening bleeding.
